

**Post-traumatic stress disorder (PTSD) (update) Committee meeting  
3**

**Date:** 26/01/2017  
**Location:** RCOG, London  
**Minutes:** Confirmed

<b>Committee members present:</b>	
Steve Hajioff, Chair (SH)	(Present for notes 1 – 6)
Philip Bell (PB)	(Present for notes 1 – 6)
Gita Bhutani (GB)	(Present for notes 1 – 6)
Sharif El-Leithy (SEL)	(Present for notes 1 – 6)
Neil Greenberg (NGb)	(Present for notes 1 – 6)
Cornelius Katona (CK)	(Present for notes 1 – 6)
Richard Meiser-Stedman (RMS)	(Present for notes 1 – 6)
Victoria Touzel (VT)	(Present for notes 1 – 6)
David Trickey (DT)	(Present for notes 1 – 6)

#### 4.0.03 DOC Cmte minutes

<b>In attendance:</b>		
Clifford Middleton until 11.30 (CM)	NICE Guidelines Commissioning Manager	(Present for notes 1 – 4)
Erin Whittingham (EW)	NICE Public Involvement Programme	(Present for notes 1 – 5)
Anne Carty (AC)	NGA Project Manager	(Present for notes 1 – 6)
Odette Megnin-Viggars (OMV)	NGA Senior Systematic Reviewer	(Present for notes 1 – 6)
Ifigeneia Mavranouzouli (IM) from 10.55	NGA Senior Health Economist	(Present for notes 4 – 6)
Moira Mugglestone (MM)	NGA Director and Guideline Lead	(Present for notes 1 – 6)
Steve Pilling until 15.00 (SP)	NGA Clinical Advisor	(Present for notes 1 – 5)
Emma Seymour (ES)	NGA Assistant Systematic Reviewer	(Present for notes 1 – 6)
Hilary Eadon (until 11.30)	NGA Guideline Lead	(Present for notes 1 – 4)

<b>Apologies:</b>	
Nick Grey (NGy)	Committee member
Jonathan Leach (JL)	Committee member
Andy Pike (AP)	Committee member
Rebecca Regler (RR)	Committee member
Sadia Janjua (SJ)	NGA Systematic Reviewer

#### **1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the third meeting for the post-traumatic stress disorder (PTSD) guideline update.

The Chair informed the Committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included:

- Presentation of evidence on pharmacological prevention and treatment of PTSD in adults
- Drafting recommendations on pharmacological prevention and treatment of

#### 4.0.03 DOC Cmte minutes

PTSD in adults				
<ul style="list-style-type: none"><li>• Discussing potential further work with children and young people with PTSD and their families and carers</li></ul>				
<b>2. Confirmation of matter under discussion, and declarations of interest</b>				
The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was PTSD.				
The Chair asked everyone to verbally declare any interests.				
<b>Name</b>	<b>Job title, organisation</b>	<b>Declarations of Interest, date declared</b>	<b>Type of interest</b>	<b>Decision taken</b>
Philip Bell	Lay member	Involved in curriculum training for mental health module at University of Bangor	Personal, non-financial, specific	Declare and participate
The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.				
<b>3. Minutes of last meeting</b>				
The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.				
<b>4. Presentations</b>				
The Chair introduced OMV and ES who gave a presentation on the evidence found for anti-depressants and anti-convulsants for the pharmacological treatment of PTSD in adults. OMV and ES took questions from the Committee.				
The Chair introduced IM who gave a presentation on the health economic evidence found for anti-convulsants for the pharmacological treatment of PTSD in adults. IM took questions from the Committee.				
The Chair introduced ES who gave a presentation on the evidence found for the pharmacological prevention of PTSD in adults. ES took questions from the Committee.				
<b>5. Questions and discussion</b>				
The Committee discussed the evidence for anti-depressants and anti-convulsants in				

#### 4.0.03 DOC Cmte minutes

the pharmacological treatment of PTSD in adults and drafted recommendations based on the evidence.

The Committee discussed the evidence for the pharmacological prevention of PTSD in adults and drafted recommendations based on the evidence.

#### **6. Any other business**

The Chair informed the Committee that the next meeting would be on 9<sup>th</sup> March 2017.

**Date of next meeting:** 09/03/2017

**Location of next meeting:** RCOG, London